A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

计划入组 401 人 · 首次发布于 2023 年 8 月 24 日

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

计划入组 1,400 人 · 首次发布于 2025 年 5 月 29 日

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

计划入组 800 人 · 首次发布于 2025 年 5 月 15 日

Orforglipron

Calcium

<dd class="col-xl-8 col-md-9 col-sm-8">Ca</dd>

Calcium cation

Ca

Hebei Changshan Biochemical Pharmaceutical Co., Ltd

China

ZHEJIANG HISUN PHARMACEUTICAL CO.,LTD

China

Zhejiang Jingxin Pharmachutical Co.,ltd.

China

Oral GLP-1R Obesity Drugs Race to Market as Novo Nordisk and Eli Lilly Lead Phase III Trials

Orforglipron Shows Promise in Reducing Cardiovascular and Inflammatory Markers in Phase II Trial

Eli Lilly's Orforglipron Shows Promise as Oral GLP-1 Therapy Advances